AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00693160
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive a remifentanil infusion
Trial: NCT00820573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 6 weeks
Trial: NCT02063035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single topical application of matching placebo, which is 100 mL of normal saline.
Trial: NCT01129258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
Trial: NCT03423771
Drug: NPF-08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution
Trial: NCT00973973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets taken orally once a day
Trial: NCT00817063
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
Trial: NCT00817063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive matching placebo for up to 24 weeks
Trial: NCT02772588
Drug: ARN-509
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03332732
Drug: VNRX-5133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactamase inhibitor
Trial: NCT03332732
Drug: VNRX-5022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approved β-lactam antibiotic
Trial: NCT03332732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching VNRX-5133 + VNRX-5022)
Trial: NCT05025163
Drug: 1.23% fluoride foam application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application of fluoride foam every 6 months
Trial: NCT05025163
Drug: 2.26% fluoride varnish application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application of fluoride varnish every 6 months
Trial: NCT04172558
Drug: Trimix
RxNorm normalized name: Nutrimix Mac Vented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on demand ICI of Trimix
Trial: NCT02981069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Dapagliflozin
Trial: NCT03623867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take placebo once weekly in week 0-4, and once monthly till week 48
Trial: NCT04608487
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT01958008
Drug: Placebo to BI 113608 high dose b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01958008
Drug: Placebo to BI 113608 low dose b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01958008
Drug: BI 113608 high dose b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01958008
Drug: Placebo to BI 113608 medium dose b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01958008
Drug: BI 113608 low dose b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01958008
Drug: BI 113608 medium dose b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03552263
Drug: T89 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T89 capsules (75mg), orally, twice daily.
Trial: NCT03552263
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (0mg), orally, twice daily.
Trial: NCT02028065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a single IV bolus over 10 seconds
Trial: NCT01414855
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
Trial: NCT01414855
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
Trial: NCT01971554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, capsules, oral, QD, Days 1 to 14
Trial: NCT01102660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg once daily for 2 weeks
Trial: NCT01102660
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 500 mg twice daily for 2 weeks
Trial: NCT01102660
Drug: Naproxen + PH-797804
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
Trial: NCT02892071
Drug: 22% TCA peel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
Trial: NCT02571257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00765635
Drug: drops intilation (Taponoto ® )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four drops, unique doses
Trial: NCT00765635
Drug: drops intilation (Otocerum®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four drops, unique doses
Trial: NCT00044876
Drug: CDB-2914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02641873
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg twice daily (480 mg total daily dose)
Trial: NCT00526136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01568203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo control for AMG 579 at each dose level
Trial: NCT01026597
Drug: REGN727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Trial: NCT01026597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Trial: NCT02614196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00805896
Drug: Songyou
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g/pack
Trial: NCT00805896
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g/pack
Trial: NCT01277640
Drug: universal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days
Trial: NCT00718224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Trial: NCT00000321
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002909
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01773785
Drug: SPI-1620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
Trial: NCT00956254
Drug: Fentanyl sublingual spray
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
Trial: NCT01678677
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Trial: NCT03685409
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch Placebo oral tablets will be given once daily to the control group
Trial: NCT00361595
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg zoledronic acid administered in a single 15 minute IV
Trial: NCT00535925
Drug: SoC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients have to be treated according the standard good medical practice by any center
Trial: NCT02396888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the wound surface was treated daily with 0.1 cc of normal saline.
Trial: NCT00535925
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypercholesterolemia:~- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die
Trial: NCT01614093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- Sugar pill
Trial: NCT04097444
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04097444
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02380755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill orally daily during 12 weeks
Trial: NCT02579226
Drug: AZD2811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
Trial: NCT02502643
Drug: OK-432 pleurodesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
Trial: NCT02796105
Drug: Progevera
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02131077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02856594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00140595
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00140595
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05063630
Drug: Medical treatment alone
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
Trial: NCT00835796
Drug: PROSCAR® 5mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg, single dose fasting
Trial: NCT02095522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02343627
Drug: NVXT Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Trial: NCT04208698
Drug: Placebo for CIN-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00159471
Drug: capecitabine, gemcitabine, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00076284
Drug: GW873140
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00576927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00014469
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02654522
Drug: Hylenex
RxNorm normalized name: Hylenex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
Trial: NCT00774644
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00965757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
Trial: NCT00225173
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
Trial: NCT00225173
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
Trial: NCT02384889
Drug: Difluoromethylornithine
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Therapy with DFMO
Trial: NCT02384889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparitor
Trial: NCT02356224
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
Trial: NCT02356224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
Trial: NCT02164812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03329950
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
Trial: NCT00540826
Drug: stimulants (any approved ADHD medication)
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in-label use
Trial: NCT03942848
Drug: zicotinide followed by placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
Trial: NCT03942848
Drug: Placebo followed by zicotinide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
Trial: NCT03057431
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 3 years
Trial: NCT03057431
Drug: 12.5 mg hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 3 years
Trial: NCT03057431
Drug: 25.0 mg hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 3 years
Trial: NCT03057431
Drug: 50.0 mg hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 3 years
Trial: NCT01217840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill - 3 pills every 12 weeks for total of 24 weeks
Trial: NCT00935753
Drug: sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
Trial: NCT01754623
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
Trial: NCT02429583
Drug: Recombivax
RxNorm normalized name: Recombivax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
Trial: NCT03275376
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin or placebo will be administered according to randomized allocations.
Trial: NCT01798004
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01798004
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02527213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
Trial: NCT03431558
Drug: Glucon-D 99.4% (Placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
Trial: NCT03864432
Drug: Gemiglptin 50mg multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin 50mg 1T \* 10days
Trial: NCT00311610
Drug: SN-38 liposome
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
Trial: NCT03187197
Drug: Pradaxa®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate
Trial: NCT02840162
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
Trial: NCT02840162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02325180
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229084
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
Trial: NCT02229084
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
Trial: NCT01087502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
Trial: NCT01087502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
Trial: NCT03019822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to the other drugs
Trial: NCT02192931
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02498860
Drug: Pemebit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
Trial: NCT01370460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL 0.9% sterile saline